Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Establishing the Use of DARWEN AI Technology in Ophthalmology and Identifying Predictors of Treatment Intervals in nAMD and RVO

NCT06495203 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06495203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06495203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Establishing the Use of DARWEN AI Technology in Ophthalmology and Identifying Predictors of Treatment Intervals in nAMD and RVO
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
November 2, 2023
Completion date
February 29, 2024
Enrollment
1,350 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration, retinal vein occlusion